Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
4(67%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_3
4
67%
Ph phase_1
1
17%
Ph phase_2
1
17%

Phase Distribution

1

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
4(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Recruiting4
Completed2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 34 (66.7%)

Trials by Status

completed233%
recruiting467%

Recent Activity

4 active trials
Showing 5 of 6
completedphase_2

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

NCT06077656
recruitingphase_3

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

NCT06855160
recruitingphase_3

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

NCT06806137
recruitingphase_3

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

NCT06740630
recruitingphase_3

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

NCT06693895
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06077656Phase 2

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Completed
NCT06855160Phase 3

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Recruiting
NCT06806137Phase 3

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

Recruiting
NCT06740630Phase 3

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Recruiting
NCT06693895Phase 3

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

Recruiting
NCT05540028Phase 1

Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6